Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease

Charu Sabharwal; Vani Sundaraiyer; Yahong Peng; Lisa Moyer; Todd J Belanger; Bradford D Gessner; Luis Jodar; Kathrin U Jansen; William C Gruber; Daniel A Scott; Wendy Watson

doi:10.1080/21645515.2022.2126253

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease

Hum Vaccin Immunother. 2022 Nov 30;18(6):2126253. doi: 10.1080/21645515.2022.2126253. Epub 2022 Nov 11.

Authors

Affiliations

¹ Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
² Biostatistics, Syneos Health, Somerset, NJ, USA.
³ Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.
⁴ Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.

Abstract

NCT03760146, NCT03828617.

Keywords: 20-valent; Clinical trial; Streptococcus pneumoniae; at-risk; immunogenicity; invasive pneumococcal disease; pneumococcal conjugate vaccine.

Publication types

Clinical Trial

MeSH terms

Adolescent
Adult
Antibodies, Bacterial
Humans
Immunogenicity, Vaccine
Middle Aged
Pneumococcal Infections* / prevention & control
Pneumococcal Vaccines*
Streptococcus pneumoniae
Vaccines, Conjugate
Young Adult

Substances

Antibodies, Bacterial
Pneumococcal Vaccines
Vaccines, Conjugate

Associated data

ClinicalTrials.gov/NCT03828617
ClinicalTrials.gov/NCT03760146

Grants and funding

This study was supported by Pfizer Inc. Medical writing support was provided by Sheena Hunt, PhD, of ICON (Blue Bell, PA, USA), and was funded by Pfizer Inc.